DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Adenocarcinoma - GEJ Clinical Trial

Official title:
A Phase 2, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)

Status Completed

Clinical Trial Summary

This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer. They must have human epidermal growth factor receptor 2 (HER2)-positive gastric or gastro-esophageal junction (GEJ) cancer: - that cannot be removed surgically - that has moved to other parts of the body - that got worse during or after treatment that included trastuzumab The study will enroll about 80 participants. Sites will be in North America and the European Union.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Adenocarcinoma - GEJ
Adenocarcinoma Gastric Stage IV With Metastases

Clinical Trial Details

NCT number	NCT04014075
Study type	Interventional
Source	Daiichi Sankyo
Contact
Status	Completed
Phase	Phase 2
Start date	November 26, 2019
Completion date	February 13, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04984733` - Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer	Phase 2
Recruiting	`NCT05315830` - A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric	Phase 1
Recruiting	`NCT06059495` - Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study	Phase 2